Scalp Hair 17-Hydroxyprogesterone And Androstenedione As A Long-Term Therapy Monitoring Tool In Congenital Adrenal Hyperplasia
April 2016
in “
Clinical Endocrinology
”
TLDR Scalp hair 17-OHP and androstenedione levels can help monitor treatment in CAH patients.
The study investigated the use of scalp hair steroid precursor concentrations, specifically 17-hydroxyprogesterone (17-OHP) and androstenedione, as a tool for monitoring treatment in children with congenital adrenal hyperplasia (CAH). The research involved 26 children with CAH, 12 patient controls with adrenal insufficiency (AI), and 293 healthy controls. Results indicated that hair cortisol concentrations were higher in children with CAH compared to both healthy and AI controls. Strong correlations were found between hair and serum/saliva concentrations of androstenedione and 17-OHP. The study concluded that measuring these concentrations in scalp hair could be a promising method for monitoring CAH treatment.